Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
DFBCat. No. 1625 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: 3,3'-Difluorobenzaldazine Chemical Name: [(3-Fluorophenyl)methylene]hydrazone-3-fluorobenzaldehyde |
Biological Activity
Novel allosteric potentiator of the metabotropic glutamate receptor mGlu5. Devoid of agonist activity itself, but potentiates (3 - 6-fold) the action of agonists at mGlu5 without any effect at other mGlu subtypes (EC50 for potentiation = 2 - 5.3 μM).Certificate of Analysis / Safety Data Sheet
References
Williams et al (2002) DFB, an allosteric potentiator of mGluR5 4th International Meeting on Metabotropic Glutamat.
O'Brien et al (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol.Pharmacol. 64 731. PMID: 12920211.
Zhang et al (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J.Pharmacol.Exp.Ther. 315 1212. PMID: 16135701.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: DFB, supplier, Allosteric, potentiators, mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
mGlu Receptors Review
Written by Francine Acher, an expert in the field. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Selective negative allosteric modulator of group II mGlu receptors
VU 0285683Negative allosteric modulator at mGlu5
Tocris Events
Meet your representative
The Role of Cytokines and Signaling in Inflammation
October 15, 2013
Bonn, Germany